Human T-cell leukemia virus type-1 (HTLV-1) is a replication-competent human retrovirus associated with two distinct types of disease only in a minority of infected individuals: the malignancy known as adult T-cell leukemia (ATL) and a chronic inflammatory central nervous system disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP is a chronic progressive myelopathy characterized by spastic paraparesis, sphincter dysfunction, and mild sensory disturbance in the lower extremities. Although the factors that cause these different manifestations of HTLV-1 infection are not fully understood, accumulating evidence from host population genetics, viral genetics, DNA expression microarrays, and assays of lymphocyte function suggests that complex virus-host interactions and the host immune response play an important role in the pathogenesis of HAM/TSP. Especially, the efficiency of an individual's cytotoxic T-cell (CTL) response to HTLV-1 limits the HTLV-1 proviral load and the risk of HAM/TSP. This paper focuses on the recent advances in HAM/TSP research with the aim to identify the precise mechanisms of disease, in order to develop effective treatment and prevention.
Keyphrases
- endothelial cells
- spinal cord
- immune response
- acute myeloid leukemia
- bone marrow
- induced pluripotent stem cells
- cerebral palsy
- oxidative stress
- pluripotent stem cells
- multiple sclerosis
- poor prognosis
- sars cov
- upper limb
- spinal cord injury
- botulinum toxin
- toll like receptor
- high throughput
- peripheral blood
- single molecule
- cerebrospinal fluid
- young adults
- disease virus
- circulating tumor
- drug induced
- single cell